目的:人们对远程医疗(TM)作为物理咨询替代方案的潜力越来越感兴趣。尽管许多研究证明了TM在风湿病中的益处,在西班牙没有关于其实施的建议。这项研究的目的是分析TM在西班牙风湿病咨询中的应用。
方法:定性,横截面,两轮查询中使用Delphi方法进行多中心研究。设计了一份结构化的临时问卷,其中包括关于远程会诊的声明,护理远程会诊,电信,远程康复,远程放射学,远程健康远程教育,主要障碍,远程健康远程教育和TM在类风湿关节炎中的优缺点。参与者是在西班牙执业的风湿病学专家。
结果:参与的风湿病专家(N=80)的平均年龄为42.4(±9.0)岁,12.6(±8.4)年的经验。获得最大共识的TM的一些方面是:TM对某些患者的随访有用,为了帮助确定是否有必要进行面对面的咨询,或协助类风湿关节炎患者,如果他们表现出低活性或缓解;某些患者,例如那些在第一次咨询中或那些存在数字障碍或认知恶化的人,应该面对面观察;TM提出了一些技术和患者访问障碍;TM在护理和继续医学教育中很有用。
结论:TM可用于风湿性疾病患者的治疗和随访。以及减轻风湿病的面对面护理负担。
OBJECTIVE: There is growing interest in the potential of telemedicine (TM) as an alternative to physical consultation. Although numerous studies prove the benefits of TM in rheumatology, there are no recommendations on its implementation in Spain. The aim of this
study was to analyze the application of TM in rheumatology consultations in Spain.
METHODS: Qualitative, cross-sectional, multicenter
study with Delphi methodology in two rounds of queries. A structured ad hoc questionnaire was designed that included statements on teleconsultation, nursing teleconsultation, telecare, telerehabilitation, teleradiology, telehealth tele-education, main barriers, advantages and disadvantages of telehealth tele-education and TM in rheumatoid arthritis. The participants were rheumatology specialists practicing in Spain.
RESULTS: The participating rheumatologists (N = 80) had a mean age of 42.4 (±9.0) years, with 12.6 (±8.4) years of experience. Some of the aspects of TM that obtained the greatest consensus were: TM is useful for follow-up of some patients, to help determine if a face-to-face consultation is necessary, or to assist patients with rheumatoid arthritis if they present low activity or in remission; certain patients, such as those in their first consultation or those who present digital barriers or cognitive deterioration, should be seen face-to-face; TM presents some technical and patient access barriers; TM can be useful in nursing and in continued medical education.
CONCLUSIONS: TM can be beneficial for the treatment and follow-up of patients with rheumatic diseases, as well as for alleviating the face-to-face care burden in rheumatology.